MedTrace Logo

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

NCT00418691 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-09-23

Study results available
· View outcomes & findings →

Summary

Primary Objective:

* To assess the efficacy of immediate release methylphenidate, sustained release methylphenidate, and the novel vigilance enhancing drug modafinil for the improvement of cognitive functioning in patients with brain tumors.

Conditions

Interventions

DRUG

IR Methylphenidate

10 mg by mouth (PO) twice daily x 4 Weeks

DRUG

Modafinil

200 mg PO Once Daily x 4 Weeks

DRUG

SR Methylphenidate

18 mg PO Once Daily x 4 Weeks

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jeffrey S. Wefel, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418691 on ClinicalTrials.gov